Regeneron and Intellia Therapeutics Will Develop CRISPR/Cas



XLV large-cap stocks

The large-cap stocks of the Health Care Select Sector SPDR ETF (XLV) returned 0.9%. They replicated the performance of the SPDR S&P 500 ETF (SPY). As of April 12, 2016, XLV holds 50 large-cap stocks in its portfolio. This shows that 89% of its holdings are large-cap stocks. Among the large-cap stocks, 45 stocks advanced and five stocks ended lower than the previous day’s closing. Large-cap stocks account for 98.5% of XLV’s portfolio.

The above graph shows the daily changes of XLV’s large-cap stocks, XLV, and SPY. So far, XLV large-cap stocks outperformed SPY in April with returns of 2.3% and 0.2%, respectively.

Article continues below advertisement

Developing CRISPR/Cas

In a press release, Regeneron Pharmaceuticals (REGN) announced that “a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. Under the terms of the six-year agreement, Regeneron has the exclusive right to discover and develop CRISPR-based products against up to 10 targets, focused primarily on therapies for a broad range of diseases that may be treated by editing genes in the liver.” Intellia will receive $75 million upfront. It’s eligible to receive significant milestone and royalty payments on potential Regeneron products.

Regeneron rose by 3% and closed at $408.07. It was trading above its 20-day moving average. However, the stock is still down by 24.8% year-to-date. Regeneron Pharmaceuticals has a book value of $34.92 per share. With its current price, the stock is trading at a price-to-book value ratio of ~11.68x. Regeneron Pharmaceuticals has a 2016 forward PE (price-to-earnings) multiple of ~35.2x. This is higher compared to some of its peers such as Celgene (CELG), Amgen (AMGN), and Gilead Sciences (GILD). They’re trading at a 2016 forward PE ratio of ~18.5x, 14.6x, and 7.9x, respectively. Regeneron Pharmaceuticals has a weight of ~1.2% in XLV’s portfolio.


More From Market Realist